Literature DB >> 9123261

Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up.

G V Mazariegos1, J Reyes, I Marino, B Flynn, J J Fung, T E Starzl.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9123261      PMCID： PMC2974269          DOI： 10.1016/s0041-1345(96)00535-0

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  12 in total

Review 1.  Cell migration, chimerism, and graft acceptance.

Authors:  T E Starzl; A J Demetris; N Murase; S Ildstad; C Ricordi; M Trucco
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Donor-type microchimerism associated with graft rejection eight years after liver transplantation.

Authors:  H J Schlitt; J Hundrieser; B Ringe; R Pichlmayr
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

Review 4.  Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.

Authors:  T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

5.  Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study.

Authors:  G V Mazariegos; H Ramos; R Shapiro; A Zeevi; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

6.  Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.

Authors:  A J Demetris; J J Fung; S Todo; J McCauley; A Jain; S Takaya; M Alessiani; K Abu-Elmagd; D H Van Thiel; T E Starzl
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

7.  Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation.

Authors:  O Pappo; H Ramos; T E Starzl; J J Fung; A J Demetris
Journal:  Am J Surg Pathol       Date:  1995-02       Impact factor: 6.394

8.  Weaning of immunosuppression in long-term liver transplant recipients.

Authors:  H C Ramos; J Reyes; K Abu-Elmagd; A Zeevi; N Reinsmoen; A Tzakis; A J Demetris; J J Fung; B Flynn; J McMichael
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

9.  Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor-specific microchimerism.

Authors:  J P Molleston; Y G Alevy; K S SivaSai; T Mohanakumar; T K Howard
Journal:  Transplantation       Date:  1996-02-27       Impact factor: 4.939

10.  Timing, significance, and prognosis of late acute liver allograft rejection.

Authors:  A C Anand; S G Hubscher; B K Gunson; P McMaster; J M Neuberger
Journal:  Transplantation       Date:  1995-11-27       Impact factor: 4.939
View more
  9 in total

1.  A modern Cosmas and Damian: Sir Roy Calne and Thomas Starzl receive the 2012 Lasker~Debakey Clinical Medical Research Award.

Authors:  Jillian Hurst
Journal:  J Clin Invest       Date:  2012-10       Impact factor: 14.808

2.  "It can't be done".

Authors:  Roy Y Calne
Journal:  Nat Med       Date:  2012-10       Impact factor: 53.440

Review 3.  Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?

Authors:  Roberta Angelico; Alessandro Parente; Tommaso Maria Manzia
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

Review 4.  Live Vaccines in Pediatric Liver Transplant Recipients: "To Give or Not to Give".

Authors:  Sarah Kemme; Taisa J Kohut; Julia M Boster; Tamir Diamond; Elizabeth B Rand; Amy G Feldman
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-10-27

5.  Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.

Authors:  Josh Levitsky; Joshua Miller; Edward Wang; Anne Rosen; Cathy Flaa; Michael Abecassis; James Mathew; Anat Tambur
Journal:  Hum Immunol       Date:  2009-01-12       Impact factor: 2.850

6.  Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea.

Authors:  Jee Hyun Lee; Suk-Koo Lee; Hae Jeong Lee; Jeong Meen Seo; Jae Won Joh; Sung Joo Kim; Choon Hyuck Kwon; Yon Ho Choe
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

7.  Health status in young adults two decades after pediatric liver transplantation.

Authors:  S Mohammad; L Hormaza; K Neighbors; P Boone; M Tierney; R K Azzam; Z Butt; E M Alonso
Journal:  Am J Transplant       Date:  2012-05-08       Impact factor: 8.086

8.  Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.

Authors:  B van Etten; A M M Eggermont; G Ambagtsheer; S T van Tiel; T L M ten Hagen
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

Review 9.  Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.

Authors:  Xiaoxiao Du; Sheng Chang; Wenzhi Guo; Shuijun Zhang; Zhonghua Klaus Chen
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.